ACR Updates: COVID-19

 

Latest COVID-19 News

Updated Information from the American College of Rheumatology Regarding Vaccination Against SARS-CoV-2

As of April 14, 2021, three vaccines have been granted emergency use authorization (EUA) from the US Food and Drug Administration (FDA) to prevent COVID-19 caused by SARS- CoV-2. There are at least 18 vaccines in Phase 3 testing worldwide with over 200 additional vaccine candidates in development. This document will discuss vaccine development and patient education.
Updated ACR Information Regarding Vaccination Against SARS-CoV-2  - Updated April 14, 2021

COVID-19 Vaccine Clinical Guidance Now Available

The ACR has developed new guidance for rheumatology providers on the use of the COVID-19 vaccines for patients with rheumatic and musculoskeletal diseases. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Vaccine Clinical Guidance Summary - Updated March 4, 2021

Provider Relief Fund Reporting Portal Fact Sheet

Organizations that received Provider Relief Fund (PRF) payments from the Department of Health and Human Services (HHS) must register in the PRF Reporting Portal. While there is not a set deadline to register, organizations are encouraged to enter their information to receive forthcoming notices about requirements.
PRF Reporting Portal Fact Sheet - February 3, 2021

Second Draw of Paycheck Protection Program Loans Fact Sheet

The Small Business Administration recently released guidance on changes to the Paycheck Protection Program (PPP) as well as information regarding a Second Draw of PPP Loans. Learn what you need to know before next week, including eligibility requirements, the amount you can receive, how funds are to be used, and what the application process looks like.
Second Draw PPP Loans Fact Sheet - January 12, 2021

See All Breaking COVID-19 News

 

Practice and Advocacy Resources

ACR COVID-19 practice and advocacy resourcesThe ACR’s COVID-19 Practice and Advocacy Task Force continues to work rapidly to provide support to you during this unprecedented time. You’ll find guidance documents that include approaches to drug shortages, support for telehealth, information about federal stimulus relief aid, and guidance for infusions. Working with experts in COVID-related topics, we are focused on developing meaningful information and resources to help guide you.
Practice and Advocacy Resources

COVID-19 Manufacturer Resources and Patient Assistance Programs  

 

New: COVID-19 Vaccine Clinical Guidance

ACR COVID-19 Vaccine Clinical GuidanceThe ACR has developed new guidance for rheumatology providers on the use of the COVID-19 vaccine for patients with rheumatic and musculoskeletal diseases (RMDs). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
COVID-19 Vaccine Clinical Guidance Summary - Updated March 4, 2021

ACR on Air Podcast with lead author, Jeffery Curtis, MD, MPH 

ACR COVID-19 Vaccine Guidance Town Hall Recording

Press Release: ACR COVID-19 Vaccine Guidance Recommends Vaccination, Addresses Immunosuppressant Drugs & Patient Concerns

 

Clinical Guidance for Pediatric Patients

ACR COVID-19 clinical guidance for pediatric patients with rheumatic diseasesThe ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic, including for the care of children with pediatric rheumatic disease, and for the management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance for Pediatric Patients

 

 

Clinical Guidance for Adult Patients with Rheumatic Diseases

ACR COVID-19 clinical guidance for patients with rheumatic diseasesThe ACR has developed clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic. Populations considered include patients with a documented COVID-19 infection, those who are stable following exposure to SARS-CoV-2 (but without known infection), and patients who are stable with no infection or exposure. The recommendations address various treatment options and provide general guidance, as well as direction for when to start, stop, or reduce medications. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance for Adult Patients with Rheumatic Diseases

 

Global Rheumatology Alliance

COVID-19 Global Rheumatology AllianceThe COVID-19 Global Rheumatology Alliance, a section of the American College of Rheumatology, is a provider-entered registry aiming to collect data on rheumatology patients with COVID-19 and hopes the information will provide guidance for rheumatology professionals when assessing and treating the infection in patients with rheumatic disease.
The Global Rheumatology Community’s Response to the Worldwide COVID-19 Pandemic  

Help Us Help Patients: Report a COVID-19 Case  

 

Questions and Feedback

Are you experiencing COVID-19 related drug shortages, practice issues, or any other problems? Share your comments and questions with us at COVID@rheumatology.org

Thank you to the corporate supporters of the ACR COVID-19 Emergency Response.

Updated April 15, 2021 at 3:30 PM ET

© 2021 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us